You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.
At the beginning of 2020, we expected Q3 financial reports for American cannabis operators to be very strong with the vaping crisis long behind us, but we certainly had our doubts when the pandemic hit. We reiterated our bullish outlook in May, and we have been reporting strong demand for legal cannabis for many months subsequently. Still, the growth that the leading publicly traded companies demonstrated in Q3 has exceeded our greatest expectations.
For those not paying close attention, New Cannabis Ventures provides a handy scorecard in its Public Cannabis Company Revenue & Income Tracker. The top 10 American companies in terms of reported quarterly revenue, which ranged from $45.5 million to as much as $352 million, all showed double-digit sequential growth:
Of these ten companies, seven are MSOs (combined Q3 revenue of $784 million), two are ancillary, and one, GW Pharma, sells cannabis-derived FDA approved medicine. Not a single company reported below analyst expectations, and some blew them away. An important sign of the maturation of the industry is that the majority of these companies are producing positive operating profits, with all of them improving from Q2. Most of the companies beyond the top 10 are also exhibiting strong growth and improving profitability.
One of big takeaways we have is that it’s becoming increasingly important for investors to understand the geographical exposure of the companies in which they invest. We note that acquisitions boosted the revenue growth for Columbia Care and Curaleaf among the MSOs, but the strongest organic growth was from operators in supply-constrained markets. For example, GTI and Cresco benefited from new production capacity becoming available in Illinois and Pennsylvania, though their growth was also supported by strength across their operations. One challenge analysts are encountering is that most companies aren’t providing granular detail regarding revenue generation by geography or, perhaps more importantly, gross margins or EBITDA margins by state. Still, listening to the calls has been very helpful in assessing the overall market dynamics state-by-state.
Our second observation is that management teams remain very optimistic about the near-term trajectory of their business. A universal refrain was the challenge of how to pick which market merits the most additional capital investment for expansion. With that said, we were disappointed that so few companies provided guidance for 2021. The two ancillary companies above both did so, but none of the MSOs did. We had expected especially Curaleaf to check off on the $1.3 billion consensus, but it punted until its Q4 report, citing too much uncertainty about the timing of Arizona and New Jersey implementing their new adult-use programs. TerrAscend joined Jushi Holdings in being among the only MSOs providing 2021 outlooks when it reported last week. Among ancillary companies, KushCo Holdings has provided its revenue and EBITDA outlook as well.
Finally, we couldn’t help but notice how much tax the MSOs are paying. We discussed the punitive nature of 280E three months ago. The effective tax-rate for Trulieve, for example, was 82%. 280E won’t last forever, but, as long as it does, it is robbing the industry of capital that could be reinvested into the business.
As we approach the Thanksgiving Day celebration this week, we want to take a moment to thank our readers for your continued support. We also want to express our gratitude to all who are advancing the cannabis industry, including those who are voting to legalize at the state and local levels, the regulators who are overseeing the industry grow responsibly, those providing capital to the industry, the patients and consumers who are pushing companies to be better and especially to the people who are working in the industry to help it fulfill its promise. We were deemed essential, and the operators proved we deserved that honor. This has been a year of great challenges, but also one of tremendous opportunity.
Ayr Strategies is an expanding vertically integrated MSO, focusing on high-growth markets and is one of the most profitable vertically integrated cannabis companies with anchor market positions in Nevada and Massachusetts and with recent entry into Pennsylvania, Ohio and Arizona through acquisitions. The company cultivates and manufactures branded cannabis products for distribution through its network of retail outlets and through third-party stores. Ayr has a strict focus on limited license & highly populated states with a robust pipeline of M&A opportunities by virtue of being the acquirer of choice.
Get up to speed by visiting the Ayr Strategies Investor Dashboard that we maintain on their behalf as a client of New Cannabis Ventures. Click the blue Follow Company button in order to stay up to date with their progress.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Ayr Strategies Q3 Revenue Increases 61% Sequentially to $45.5 Million
- Exclusive: Canadian Cannabis Sales Increase 108% in September to C$256 Million
- Cresco Labs Q3 Revenue Soars 63% Sequentially to $153 Million
- Curaleaf Q3 Revenue Increases 55% to $182 Million
- Greenlane Cannabis Revenue Increases 7% Sequentially to $32.3 Million in Q3
- Harborside Q3 Gross Revenue Increases 21% Sequentially to $19.6 Million
- Exclusive: How the New Supreme Cannabis CEO Is Turning the Company Around
- Exclusive: Jushi Holdings Is Set to Capitalize on Its Third Big Cannabis Market Opportunity
- TerrAscend Boosts 2020 Outlook and Projects 2021 Revenue in Excess of C$360 Million
- TILT Holdings Q3 Revenue Increases 5% Sequentially to $40.4 Million and Company Divests Blackbird Subsidiary
- Trulieve Q3 Revenue Increases 13% Sequentially to $136.3 Million
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.
View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than US$10M per quarter.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Alan & Joel